Relmada Therapeutics RLMD
NASDAQ RLMD
$3.73 -0.06 (-1.58%)
At close: Sep 29, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)

Updated

Relmada Therapeutics' Research & Development was $8.39 million in Q2 2026, up 197.7% from $2.82 million a year earlier and up 3.8% from the prior quarter.

Analysis

Relmada Therapeutics (RLMD) Research & Development (2014 - 2026) Analysis & Trends

On a trailing twelve-month basis, Relmada Therapeutics' Research & Development was $28.59 million through Jun 30, 2026, down 22.6% year-over-year; for FY2025, it was $26.88 million, down 41.8% from FY2024.

  • Research & Development has now declined for three consecutive years, with a five-year compound annual growth rate of -5.7% (FY2020 to FY2025).
  • In earlier years, Research & Development was $46.18 million in FY2024 (-15.7%), $54.81 million in FY2023 (-51.6%), $113.32 million in FY2022 (+25.1%) and $90.62 million in FY2021 (+151.9%).
  • The Q2 2026 figure marks the highest quarterly Research & Development since Q1 2025.
  • Compared with a year earlier, Research & Development was higher in two of the last eight quarters, with an average decline of 3.5%.
  • The best year-over-year quarter for Research & Development over five years was Q3 2021 (growth of 202.5%); the worst was Q2 2025 (a decline of 73.7%).
  • Per Business Quant data, RLMD's Research & Development in the three quarters before Q2 2026 was $8.09 million (Q1 2026), $8.07 million (Q4 2025) and $4.04 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Relmada Therapeutics 404.28 Mn 404.28 Mn - 8.39 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8.39 Mn
Mar 31, 2026 8.09 Mn
Dec 31, 2025 8.07 Mn
Sep 30, 2025 4.04 Mn
Jun 30, 2025 2.82 Mn
Mar 31, 2025 11.95 Mn
Dec 31, 2024 11.00 Mn
Sep 30, 2024 11.15 Mn
Jun 30, 2024 10.72 Mn
Mar 31, 2024 13.31 Mn
Dec 31, 2023 14.75 Mn
Sep 30, 2023 10.45 Mn
Jun 30, 2023 13.74 Mn
Mar 31, 2023 15.86 Mn
Dec 31, 2022 26.87 Mn
Sep 30, 2022 30.53 Mn
Jun 30, 2022 30.91 Mn
Mar 31, 2022 25.01 Mn
Dec 31, 2021 25.27 Mn
Sep 30, 2021 33.99 Mn
API Access

Relmada Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=RLMD&period=max&api_key=YOUR_API_KEY